The Trilogy of SARS-CoV-2 in Pediatrics (Part 3): Thrombosis, Anticoagulant, and Antiplatelet Considerations

Area of Science:

• Pediatric Hematology
• Infectious Diseases
• Critical Care Medicine

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a hypercoagulable state affecting patients across all age groups.
• While deep vein thrombosis (DVT) is uncommon in children without risk factors, SARS-CoV-2-related illnesses, including COVID-19 and multisystem inflammatory syndrome, have been linked to coagulopathy and thrombosis in pediatric populations.
• The precise incidence of venous thromboembolism (VTE) in pediatric patients with SARS-CoV-2-related conditions remains incompletely understood.

Purpose of the Study:

• To provide a comprehensive review of SARS-CoV-2-associated coagulopathy in pediatric patients.
• To outline strategies for the optimal evaluation and management of thrombosis in children affected by SARS-CoV-2.
• To discuss preventive measures for thrombosis in pediatric patients with COVID-19 and related syndromes.

Main Methods:

• Literature review of studies on SARS-CoV-2, coagulopathy, and thrombosis in pediatric populations.
• Analysis of existing data on the incidence and clinical presentation of VTE in children with COVID-19.
• Synthesis of current guidelines and expert recommendations for thrombosis management in pediatric critical care.

Main Results:

• SARS-CoV-2 infection induces a prothrombotic state, increasing the risk of VTE in pediatric patients.
• Coagulopathy and thrombotic events have been observed in children with both acute COVID-19 and multisystem inflammatory syndrome.
• Risk factors and specific diagnostic criteria for VTE in this population require further elucidation.

Conclusions:

• Pediatric patients with SARS-CoV-2-related illnesses are at risk for developing thrombosis due to associated coagulopathy.
• A proactive approach involving careful evaluation, appropriate management, and targeted prevention strategies is crucial for optimizing outcomes.
• Further research is needed to establish definitive VTE incidence rates and refine management protocols in pediatric populations affected by SARS-CoV-2.